Market Access Understanding the evolution of container closure integrity t... At different stages of the drug lifecycle, the minimum provision for parenteral products is a safety barrier against potential contaminants.
Partner Content Partner Content Industry Gathers Next Week at Pharmaceutical Microbiology Ea... Last chance to register
Partner Content Partner Content The Power of Partnerships: Meeting Pharmaceutical Logistic E... Partnerships in the Supply Chain
Events Partner Content SMi's 12th annual Cold Chain Distribution Conference and Exh... This year's event will continue to lead.
News FDA experts lukewarm on AZ's anticoagulant antidote Andexxa AstraZeneca is facing some pushback as it tries to upgrade anticoagulant antidote drug Andexaa to full approval in the US
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends